LLC
Competencia para AMRN imagino.
LipimetiX Development, LLC, issued a press release announcing the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed a generally acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference.
«Después de nada, o después de todo/ supe que todo no era más que nada.»